Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zeprumetostat in Relapsed/Refractory Large Granular Lymphocyte Leukemia
NCT07692529Phase 1Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Oct 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of zeprumetostat in large granular lymphocyte leukemia, sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Proportion of achieving hematological remission at 8 weeks. Started Oct 2026; status: recruiting.
02
Drugs
zeprumetostat
03
Conditions
large granular lymphocyte leukemia
Beyond the preview
Go deeper on NCT07692529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07692529.